Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity

Arthritis Care and Research

Volumn 64, Issue 12, 2012, Pages 1794-1803

  Curtis, Jeffrey R ^a   Van Der Helm Van Mil, Annette H ^b   Knevel, Rachel ^b   Huizinga, Tom W ^b   Haney, Douglas J ^c   Shen, Yijing ^c   Ramanujan, Saroja ^c   Cavet, Guy ^c   Centola, Michael ^d   Hesterberg, Lyndal K ^c   Chernoff, David ^c   Ford, Kerri ^c   Shadick, Nancy A ^e   Hamburger, Max ^f   Fleischmann, Roy ^g   Keystone, Edward ^h   Weinblatt, Michael E ^e  

^a The University of Alabama at Birmingham   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Crescendo Bioscience   (United States)

^d OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f Rheumatology Associates of Long Island   (United States)

^g UNIVERSITY OF TEXAS AT DALLAS   (United States)

^h UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; METHOTREXATE; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BODY MASS; COHORT ANALYSIS; CRITERION RELATED VALIDITY; DISCRIMINANT VALIDITY; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE 28; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIBIOMARKER DISEASE ACTIVITY SCORE; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; TREATMENT RESPONSE;

ADULT; AGED; ALGORITHMS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT ACUITY; REGISTRIES; REPRODUCIBILITY OF RESULTS; RHEUMATOLOGY; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 84866433246     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.21767     Document Type: Article

References (49)

1. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64: 625-39.
2. Combe B, Landewe R, Lukas C, Bolosiu HD, Breedveld F, Dougados M, et al. EULAR recommendations for the management of early arthritis: report of a Task Force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007; 66: 34-45.
3. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69: 631-7.
4. 2012 Physician Quality Reporting System measure list and implementation guide. 2011. URL: https://www.cms.gov/PQRS/Downloads/2012-PhysQualRptg- ImplementationGuide-MeasuresList-12152011.zip.
5. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005; 52: 3381-90.
6. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004; 364: 263-9.
7. Schoels M, Knevel R, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas DT, et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis 2010; 69: 638-43.
8. Van der Heijde DM, van 't Hof MA, van Riel PL, Theunisse LA, Lubberts EW, van Leeuwen MA, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990; 49: 916-20.
9. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL,. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
10. Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003; 42: 244-57.
11. Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005; 7: R796-806.
12. Pincus T, Yazici Y, Bergman M, Maclean R, Harrington T,. A proposed continuous quality improvement approach to assessment and management of patients with rheumatoid arthritis without formal joint counts, based on quantitative Routine Assessment of Patient Index Data (RAPID) scores on a Multidimensional Health Assessment Questionnaire (MDHAQ). Best Pract Res Clin Rheumatol 2007; 21: 789-804.
13. Pincus T, Swearingen CJ, Bergman M, Yazici Y,. RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to Disease Activity Score and Clinical Disease Activity Index categories. J Rheumatol 2008; 35: 2136-47.
14. Grunke M, Antoni CE, Kavanaugh A, Hildebrand V, Dechant C, Schett G, et al. Standardization of joint examination technique leads to a significant decrease in variability among different examiners. J Rheumatol 2010; 37: 860-4.
15. Klinkhoff AV, Bellamy N, Bombardier C, Carette S, Chalmers A, Esdaile JM, et al. An experiment in reducing interobserver variability of the examination for joint tenderness. J Rheumatol 1988; 15: 492-4.
16. Van der Heijde D, Landewe R, van Vollenhoven R, Fatenejad S, Klareskog L,. Level of radiographic damage and radiographic progression are determinants of physical function: a longitudinal analysis of the TEMPO trial. Ann Rheum Dis 2008; 67: 1267-70.
17. Graudal N, Tarp U, Jurik AG, Galloe AM, Garred P, Milman N, et al. Inflammatory patterns in rheumatoid arthritis estimated by the number of swollen and tender joints, the erythrocyte sedimentation rate, and hemoglobin: longterm course and association to radiographic progression. J Rheumatol 2000; 27: 47-57.
18. Plant MJ, Williams AL, O'Sullivan MM, Lewis PA, Coles EC, Jessop JD,. Relationship between time-integrated C-reactive protein levels and radiologic progression in patients with rheumatoid arthritis. Arthritis Rheum 2000; 43: 1473-7.
19. Gabay C, Kushner I,. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-54.
20. Keenan RT, Swearingen CJ, Yazici Y,. Erythrocyte sedimentation rate and C-reactive protein levels are poorly correlated with clinical measures of disease activity in rheumatoid arthritis, systemic lupus erythematosus and osteoarthritis patients. Clin Exp Rheumatol 2008; 26: 814-9.
21. Rhodes B, Merriman ME, Harrison A, Nissen MJ, Smith M, Stamp L, et al. A genetic association study of serum acute-phase C-reactive protein levels in rheumatoid arthritis: implications for clinical interpretation. PLoS Med 2010; 7: e1000341.
22. Sokka T, Pincus T,. Erythrocyte sedimentation rate, C-reactive protein, or rheumatoid factor are normal at presentation in 35%-45% of patients with rheumatoid arthritis seen between 1980 and 2004: analyses from Finland and the United States. J Rheumatol 2009; 36: 1387-90.
23. Cavet G, Centola M, Shen Y, Haney D, Smith D, Hesterberg L, et al. Development of a multi-biomarker test for rheumatoid arthritis (RA) disease activity [abstract]. Ann Rheum Dis 2010; 69 Suppl: 148.
24. Van der Heijde DM, van 't Hof MA, van Riel PL, van Leeuwen MA, van Rijswijk MH, van de Putte LB,. Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis 1992; 51: 177-81.
25. Tugwell P, Bombardier C,. A methodologic framework for developing and selecting endpoints in clinical trials. J Rheumatol 1982; 9: 758-62.
26. Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009; 68: 954-60.
27. Fleischmann RM, Curtis JR, Hamburger MH, Blumstein H, Swan K, Cavet G, et al. RA population characteristics in InFoRM, a longitudinal observational study [abstract]. Ann Rheum Dis 2010; 69 Suppl: 657.
28. Iannaccone CK, Lee YC, Cui J, Frits ML, Glass RJ, Plenge RM, et al. Using genetic and clinical data to understand response to disease-modifying anti-rheumatic drug therapy: data from the Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study. Rheumatology (Oxford) 2010; 50: 40-6.
29. De Rooy DP, van der Linden MP, Knevel R, Huizinga TW, van der Helm-van Mil AH,. Predicting arthritis outcomes: what can be learned from the Leiden Early Arthritis Clinic? Rheumatology (Oxford) 2010; 50: 93-100.
30. Parker A, Izmailova ES, Narang J, Badola S, Le T, Roubenoff R, et al. Peripheral blood expression of nuclear factor-Îb-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-α versus methotrexate. J Rheumatol 2007; 34: 1817-22.
31. Todd DJ, Knowlton N, Amato M, Frank MB, Schur PH, Izmailova ES, et al. Erroneous augmentation of multiplex assay measurements in patients with rheumatoid arthritis due to heterophilic binding by serum rheumatoid factor. Arthritis Rheum 2011; 63: 894-903.
32. Eastman S, Manning B, Qureshi F, Cavet G, Haney D, Shen Y, et al. Assay development for precise measurement of disease activity serum biomarkers [abstract]. Ann Rheum Dis 2010; 69 Suppl: 179.
33. Bakker MF, Bijlsma JW, Jacobs JW, Haney D, Shen Y, Hesterberg LK, et al. Performance of serum biomarkers and multivariate biomarker-based test to measure disease activity in early rheumatoid arthritis treated according to the CAMERA protocol [abstract]. Ann Rheum Dis 2010; 69 Suppl: 350.
34. Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N,. Comparison of Disease Activity Score (DAS)28-erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values. Ann Rheum Dis 2007; 66: 407-9.
35. Fleiss JL, Cohen JD,. The equivalence of weighted Î and the intraclass correlation coefficient as measures of reliability. Educ Psychol Meas 1973; 33: 613-9.
36. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35.
37. Efron B,. Better bootstrap confidence intervals. J Am Stat Assoc 1987; 82: 171-85.
38. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586-93.
39. Pincus T, Swearingen CJ, Bergman MJ, Colglazier CL, Kaell AT, Kunath AM, et al. RAPID3 (Routine Assessment of Patient Index Data) on an MDHAQ (Multidimensional Health Assessment Questionnaire): agreement with DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) activity categories, scored in five versus more than ninety seconds. Arthritis Care Res (Hoboken) 2010; 62: 181-9.
40. Sullivan MB, Iannaccone C, Cui J, Lu B, Batra K, Weinblatt M, et al. Evaluation of selected rheumatoid arthritis activity scores for office-based assessment. J Rheumatol 2010; 37: 2466-8.
41. Uhlig T, Kvien TK, Pincus T,. Test-retest reliability of disease activity core set measures and indices in rheumatoid arthritis. Ann Rheum Dis 2009; 68: 972-5.
42. Cunnane G, Grehan S, Geoghegan S, McCormack C, Shields D, Whitehead AS, et al. Serum amyloid A in the assessment of early inflammatory arthritis. J Rheumatol 2000; 27: 58-63.
43. Johansen JS, Stoltenberg M, Hansen M, Florescu A, Horslev-Petersen K, Lorenzen I, et al. Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity. Rheumatology (Oxford) 1999; 38: 618-26.
44. Kurosaka D, Hirai K, Nishioka M, Miyamoto Y, Yoshida K, Noda K, et al. Clinical significance of serum levels of vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in patients with rheumatoid arthritis. J Rheumatol 2010; 37: 1121-8.
45. Lee SW, Park MC, Park YB, Lee SK,. Measurement of the serum leptin level could assist disease activity monitoring in rheumatoid arthritis. Rheumatol Int 2007; 27: 537-40.
46. Milman N, Karsh J, Booth RA,. Correlation of a multi-cytokine panel with clinical disease activity in patients with rheumatoid arthritis. Clin Biochem 2010; 43: 1309-14.
47. Tchetverikov I, Lard LR, DeGroot J, Verzijl N, TeKoppele JM, Breedveld FC, et al. Matrix metalloproteinases-3, -8, -9 as markers of disease activity and joint damage progression in early rheumatoid arthritis. Ann Rheum Dis 2003; 62: 1094-9.
48. Valle Y, Ledezma-Lozano IY, Torres-Carrillo N, Padilla-Gutierrez JR, Navarro-Hernandez RE, Vazquez-Del Mercado M, et al. Circulating TNFRI and TNFRII levels correlated with the Disease Activity Score (DAS28) in rheumatoid arthritis. Scand J Rheumatol 2009; 38: 332-5.
49. Shadick NA, Chernoff D, Hamburger M, Curtis JR, Cavet G, Ford K, et al. Robustness of a novel multi-biomarker score for RA disease activity (Vectra DA) across a spectrum of co-morbidities and smoking status [abstract]. Ann Rheum Dis 2011; 70 Suppl: 446.